United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
A Joint Model for Assessing Mortality-Adjusted Progression (MAP) in Amyotrophic Lateral Sclerosis: Application to Clinical Trials of Sodium Phenylbutyrate and Taurursodiol
Lead Author: Ruben van Eijk
Published: International Symposium on ALS/MND (MNDA)
Date: December 6 - 8, 2023
Effect of Sodium Phenylbutyrate and Taurursodiol on Plasma Concentrations of Neuroinflammatory Biomarkers in Amyotrophic Lateral Sclerosis: Results From the CENTAUR Trial
Lead Author: Robert Bowser, PhD & Jiyan An
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: December 2, 2023
Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations
Lead Author: Sara Öhrman (Presenter)
Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Date: November 12 - 15, 2023
Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease
Lead Author: Lahar Mehta, MD (Presenter)
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: October 24 - 27, 2023
Design of a Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009 ORION)
Lead Author: Günter Höglinger, MD
Published: Neuro2023
Date: October 19 - 20, 2023
Analysis of Sodium Phenylbutyrate and Taurursodiol Survival Effect in ALS Using External Controls
Lead Author: Sabrina Paganoni, MD, PhD & Melanie Quintana, PhD
Published: Annals of Clinical and Translational Neurology
Date: October 9, 2023
An In Vitro Recovery Study of Sodium Phenylbutyrate and Taurursodiol From 3 Types of Dosing Containers and Various Percutaneous Endoscopic Gastrostomy Feeding Tubes
Lead Author: Machelle Manuel, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Development of a Composite Diagnostic Biomarker for Amyotrophic Lateral Sclerosis: Experimental Approach and Progress to Date
Lead Author: Jamie Timmons, MD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Novel Neuroprotective Strategies in Human Neuron Models of ALS/FTD: Evaluating Antisense Oligonucleotide Therapies, including AMX0114
Lead Author: Sami Barmada, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Ongoing and Planned Studies to Further Elucidate the Efficacy, Safety, and Pharmacokinetics of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Jamie Timmons, MD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023